Literature DB >> 21715538

Pituitary carcinoma with malignant growth from first presentation and fulminant clinical course--case report and review of the literature.

Katarzyna Dudziak1, Jürgen Honegger, Antje Bornemann, Marius Horger, Karsten Müssig.   

Abstract

CONTEXT: Although pituitary adenomas are common, pituitary carcinoma is a very rare condition.
OBJECTIVE: We report on a 48-yr-old male presenting with pituitary carcinoma with malignant growth from the beginning and a fulminant clinical course and give an overview of the previously reported cases, paying special attention to clinical and histological parameters that may predict the clinical course.
METHODS: We performed a MEDLINE search for previously published cases of pituitary carcinoma and analyzed the clinical, laboratory, and radiological findings.
RESULTS: Ki-67 index and the number of metastatic diseases found on postmortem examination were significantly increased in patients with no treatment response compared to those with some treatment response (P = 0.03 and P = 0.02, respectively). In contrast, time to occurrence of metastatic disease and time to death were significantly shortened in patients with no treatment response (P = 0.01 and P = 0.02, respectively). No differences were found between the two groups for gender distribution, tumor size, mitotic activity assessed as the number of mitotic figures per 10 high-power fields, and number of locations of metastatic disease.
CONCLUSION: Frequently relapsing, invasive adenoma should raise a suspicion of a malignant disease. Clinically only the presence of metastases is a criterion of malignancy. A high Ki-67 index in the pituitary carcinoma and early manifestation of metastatic disease appear to predict rapid disease progression.

Entities:  

Mesh:

Year:  2011        PMID: 21715538     DOI: 10.1210/jc.2011-1166

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  21 in total

Review 1.  Corticotrophic pituitary carcinoma with cervical metastases: case series and literature review.

Authors:  Frederick Yoo; Edward C Kuan; Anthony P Heaney; Marvin Bergsneider; Marilene B Wang
Journal:  Pituitary       Date:  2018-06       Impact factor: 4.107

2.  [The 2017 WHO classification of pituitary tumors].

Authors:  Wolfgang Saeger
Journal:  Pathologe       Date:  2021-04-20       Impact factor: 1.011

3.  Progress in Endocrine Neoplasia.

Authors:  Samuel A Wells
Journal:  Clin Cancer Res       Date:  2016-10-15       Impact factor: 12.531

Review 4.  Malignant transformation in non-functioning pituitary adenomas (pituitary carcinoma).

Authors:  Nèle Lenders; Ann McCormack
Journal:  Pituitary       Date:  2018-04       Impact factor: 4.107

Review 5.  Aggressive pituitary tumours and pituitary carcinomas.

Authors:  Gérald Raverot; Mirela Diana Ilie; Hélène Lasolle; Vincent Amodru; Jacqueline Trouillas; Frédéric Castinetti; Thierry Brue
Journal:  Nat Rev Endocrinol       Date:  2021-09-07       Impact factor: 43.330

6.  Invasive adenoma and pituitary carcinoma: a SEER database analysis.

Authors:  Tara M Hansen; Sachin Batra; Michael Lim; Gary L Gallia; Peter C Burger; Roberto Salvatori; Gary Wand; Alfredo Quinones-Hinojosa; Lawrence Kleinberg; Kristin J Redmond
Journal:  Neurosurg Rev       Date:  2014-02-14       Impact factor: 3.042

Review 7.  In search of a prognostic classification of endocrine pituitary tumors.

Authors:  Jacqueline Trouillas
Journal:  Endocr Pathol       Date:  2014-06       Impact factor: 3.943

Review 8.  Approach to the Treatment of a Patient with an Aggressive Pituitary Tumor.

Authors:  Andrew L Lin; Mark T A Donoghue; Sharon L Wardlaw; T Jonathan Yang; Lisa Bodei; Viviane Tabar; Eliza B Geer
Journal:  J Clin Endocrinol Metab       Date:  2020-12-01       Impact factor: 5.958

9.  Metastatic pituitary carcinoma in a patient with acromegaly: a case report.

Authors:  Seamus Sreenan; Elizabeth Sengupta; William Tormey; Richard Landau
Journal:  J Med Case Rep       Date:  2012-09-25

10.  A case of nonfunctioning pituitary carcinoma that responded to temozolomide treatment.

Authors:  Haruko Morokuma; Takao Ando; Takuya Hayashida; Ichiro Horie; Naoko Inoshita; Fumi Murata; Ikuko Ueki; Kan Nakamura; Misa Imaizumi; Toshiro Usa; Atsushi Kawakami
Journal:  Case Rep Endocrinol       Date:  2012-10-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.